BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.
Read original at benzingaStocks · News reference
8-K filing — Outlook Therapeutics, Inc. (OTLK)
Filed: 2026-07-24 AccNo: 0001104659-26-086685 Size: 228 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Jul 24, 2026, 9:01 PM
- Checked
- Jul 24, 2026, 9:01 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
Read original at benzingaOutlook Therapeutics shares are trading lower after the company reported worse-than-expected Q3 sales results.
Read original at benzingaTranscript: Outlook Therapeutics Q3 2026 Earnings Conference Call
Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time
Read original at benzinga